Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1988 2
1989 1
1990 1
1991 2
1992 1
1993 5
1994 5
1995 21
1996 34
1997 19
1998 37
1999 21
2000 27
2001 15
2002 9
2003 11
2004 14
2005 19
2006 14
2007 18
2008 31
2009 48
2010 53
2011 46
2012 49
2013 46
2014 87
2015 114
2016 122
2017 112
2018 125
2019 107
2020 136
2021 155
2022 133
2023 125
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

1,642 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean mol cancer (126,371 results)?
Nutritional Interventions to Improve Cachexia Outcomes in Cancer-A Systematic Review.
Braha A, Albai A, Timar B, Negru Ș, Sorin S, Roman D, Popovici D. Braha A, et al. Medicina (Kaunas). 2022 Jul 21;58(7):966. doi: 10.3390/medicina58070966. Medicina (Kaunas). 2022. PMID: 35888685 Free PMC article. Review.
Background and Objectives: The prevalence of cachexia has increased across all of the cancer types and accounts for up to 20% of cancer-related deaths. ...Further studies investigating the underlying mechanisms of action of these nutritional supplements in cancer …
Background and Objectives: The prevalence of cachexia has increased across all of the cancer types and accounts for up to 20% of c …
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Wolchok JD, et al. J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24. J Clin Oncol. 2022. PMID: 34818112 Free PMC article. Clinical Trial.
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Ravi A, et al. Nat Genet. 2023 May;55(5):807-819. doi: 10.1038/s41588-023-01355-5. Epub 2023 Apr 6. Nat Genet. 2023. PMID: 37024582 Free PMC article.
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Sta …
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our underst …
[Myelofibrosis: A review].
Genthon A, Killian M, Mertz P, Cathebras P, Gimenez De Mestral S, Guyotat D, Chalayer E. Genthon A, et al. Rev Med Interne. 2021 Feb;42(2):101-109. doi: 10.1016/j.revmed.2020.08.018. Epub 2020 Nov 23. Rev Med Interne. 2021. PMID: 33243417 Review. French.
It is characterized by stem cell-derived clonal proliferation that is often, but not always, accompanied by somatic mutations, which are classified into driver mutations (JAK2, CALR, or MPL), subclonal mutations and fibrosis on bone marrow biopsy. Myelofibrosis commonly de …
It is characterized by stem cell-derived clonal proliferation that is often, but not always, accompanied by somatic mutations, which are cla …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Mosele F, et al. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020 Aug 24. Ann Oncol. 2020. PMID: 32853681 Free article. Review.
Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma. In these tumours, large multigene panels could be used i …
Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lung cancer …
Endotoxin and cancer chemo-prevention.
Mastrangelo G, Fadda E, Cegolon L. Mastrangelo G, et al. Cancer Epidemiol. 2013 Oct;37(5):528-33. doi: 10.1016/j.canep.2013.04.008. Epub 2013 May 18. Cancer Epidemiol. 2013. PMID: 23692704 Review.
Over 200,000 patients have used them to date (nearly 70% in Germany). Since detailed exposure (MPL() dose and timing of administration) and individual data are potentially available, an observational follow-up study could be conducted in Germany to investigate the protecti …
Over 200,000 patients have used them to date (nearly 70% in Germany). Since detailed exposure (MPL() dose and timing of administratio …
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Nuñez NG, et al. Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381 Free article.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce effective anti-tumor responses, they may also drive serious immune-related adverse events (irAEs). ...F …
BACKGROUND: Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cance …
Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P, Vannucchi AM. Guglielmelli P, et al. Blood Rev. 2020 Jul;42:100714. doi: 10.1016/j.blre.2020.100714. Epub 2020 Jun 3. Blood Rev. 2020. PMID: 32546373 Review.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukemia; how …
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiov …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by the European LeukemiaNet (ELN) consortium. ...Key differences from the 2011 diagnostic recommendations included: …
This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg …
Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Shahin OA, et al. Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21. Acta Haematol. 2021. PMID: 33882481 Free PMC article. Review.
BACKGROUND: Myeloproliferative neoplasms (MPNs) can transform into blast phase MPN (leukemic transformation; MPN-BP), typically via accelerated phase MPN (MPN-AP), in 20-25% of the cases. ...Higher incidence of leukemic transformation has been associated with the most aggr …
BACKGROUND: Myeloproliferative neoplasms (MPNs) can transform into blast phase MPN (leukemic transformation; MPN-BP), typically via a …
1,642 results